| Literature DB >> 25663633 |
Sandra H Hoeboer1, A B Johan Groeneveld, Noel Engels, Michel van Genderen, Bas P L Wijnhoven, Jasper van Bommel.
Abstract
BACKGROUND: Elective esophagectomy with gastric tube reconstruction carries a high risk for complications. Early and accurate diagnosis could improve patient management. Increased C-reactive protein (CRP) levels may be associated with any, surgical or infectious, complication and procalcitonin (PCT) specifically with infectious complications.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25663633 PMCID: PMC4361731 DOI: 10.1007/s11605-015-2745-z
Source DB: PubMed Journal: J Gastrointest Surg ISSN: 1091-255X Impact factor: 3.452
Roche diagnostics, Mannheim, Germany), and normal values are < 9 mg/L. PCT was measured using the PCT sensitive for the Kryptor compact system (Brahms Diagnostica, Hennigsdorf, Germany). Assays were performed according to the manufacturer’s guidelines, the lower detection limit being 0.02 ng/mL, with an upper limit in healthy volunteers of 0.05 ng/mL. The functional assay sensitivity (FAS) of this test is 0.06 ng/mL, with an intra-assay coefficient of variation (CV) and inter-assay CV of < 6 % in samples containing > 0.3 ng/mL.
Definition of complications
| Complication | Definition |
|---|---|
| Surgical | |
| Anastomotic leakage | Esophagoenteric leak confirmed by endoscopy or esophageal contrast videography that requires local treatment, surgical treatment, or removal of conduit. |
| Pleural effusion | Pleural effusion confirmed by radiology that requires drainage. |
| Chyle leak | Chylomicrons in pleura aspirate or milky discharge from chest tube at initiation of enteral feeding. |
| Laryngeal nerve palsy | Clinically suspected vocal cord paralysis confirmed by laryngoscopy. |
| Conduit ischemia/necrosis | Circular conduit ischemia/necrosis confirmed by endoscopy and/or surgically that requires local treatment or removal of conduit. |
| Thromboembolic disease | Deep venous thrombosis or pulmonary embolus. |
| Infectious | |
| Pneumonia | New infiltrate on chest radiograph and positive tracheal aspirate cultures that requires antibiotic treatment. |
| Empyema | Pleural effusion on chest radiograph and positive culture of aspirated specimen that requires antibiotic and radiological or surgical treatment. |
| Abscess | Intra-thoracic (mediastinal) or intra-abdominal abscess confirmed by radiology with positive culture of aspirated specimen that requires antibiotic, radiological, or surgical treatment. |
| Wound infection | Erythematous wound, with effluent of pus and/or positive culture that requires opening of wound and antibiotics. |
| Gastrointestinal | Stool culture positive for microbial pathogens that requires antibiotic treatment. |
| Urinary tract | Positive urine culture and urine sediment that require antibiotic treatment. |
| Bacteremia | Blood samples showing positive growth and/or positive Gram stain, not reflecting colonization that requires antibiotic treatment. |
Patients could suffer from multiple complications simultaneously
Complications up to 10 days post-esophagectomy
| Surgical complication ( | Infectious complication ( | Combined surgical/infectious complication ( |
|---|---|---|
| Anastomotic leak | Pneumonia, wound infection | Anastomotic leak, chyle leak, wound infection |
| Anastomotic leak | Pneumonia, wound infection | Anastomotic leak, pneumonia, wound infection |
| Pleural effusion, chyle leak | Pneumonia | Anastomotic leak, pneumonia |
| Chyle leak | Pneumonia | Anastomotic leak, abscess, wound infection |
| Chyle leak | Pneumonia | Anastomotic leak, pleural effusion, abscess, wound infection |
| Pneumonia | Anastomotic leak, pneumonia | |
| Pneumonia | Anastomotic leak, wound infection, pneumonia, empyema | |
| Pneumonia | Anastomotic leak, pneumonia, empyema | |
| Pneumonia | Chyle leak, abscess, pneumonia | |
| Wound infection | ||
| Wound infection | ||
| Wound infection | ||
| Urinary tract infection | ||
| Urinary tract infection |
Complications presented no sooner than day 3; in 92 % of cases, complications presented on day 4 or after
Baseline characteristics
| Uncomplicated | Complicated | ||||||
|---|---|---|---|---|---|---|---|
| ( | ( | P1 | Surgical ( | Infectious ( | Combined surgical/infectious ( | P2 | |
| Sex (M) | 16 (94) | 23 (82) | 0.39 | 2 (40) | 12 (86) | 9 (100) | 0.009 |
| Age (years) | 62 (14) | 63 (17) | 0.52 | 60 (15) | 65 (14) | 63 (20) | 0.89 |
| BMI (cm2/kg) | 27.8 (4.7) | 23.8 (5.0) | 0.05 | 22.7 (8.3) | 25.3 (6.1) | 23.5 (2.9) | 0.12 |
| WHO performance score | |||||||
| 0 | 7 (41) | 14 (50) | 0.57 | 7 (50) | 2 (40) | 5 (56) | 0.57 |
| 1 | 10 (59) | 14 (50) | 7 (50) | 3 (60) | 4 (44) | ||
| Preoperative pulmonary function | |||||||
| FEV1 (% predicted) | 113 (27) | 98 (21) | 0.04 | 96 (27) | 100 (1) | 94 (22) | 0.19 |
| VC (% predicted) | 112 (28) | 111 (16) | 1.00 | 115 (17) | 108 (2) | 106 (22) | 0.58 |
| ASA class | |||||||
| I | 2 (12) | 10 (11) | 0.86 | 2 (40) | 0 | 1 (11) | 0.08 |
| II | 13 (77) | 20 (71) | 1 (20) | 11 (79) | 8 (89) | ||
| III | 2 (12) | 5 (18) | 2 (40) | 3 (21) | 0 | ||
| P-POSSUM score | 35 (10) | 34 (5) | 0.50 | 34 (3) | 33 (8) | 35 (3) | 0.70 |
| Cell type | |||||||
| Squamous cell carcinoma | 2 (12) | 9 (32) | 0.28 | 4 (29) | 2 (40) | 3 (33) | 0.85 |
| Adenocarcinoma | 13 (77) | 18 (64) | 6 (64) | 3 (60) | 6 (67) | ||
| Small cell neuroendocrine carcinoma | 1 (6) | 1 (4) | 1 (6) | 0 | 0 | ||
| Miscellaneous | 1 (6) | 0 | 0 | 0 | 0 | ||
| Clinical stage | |||||||
| T | |||||||
| 1 | 1 (6) | 0 | 0.10 | 0 | 0 | 0 | 0.26 |
| 2 | 2 (12) | 5 (18) | 2 (14) | 1 (20) | 2 (22) | ||
| 3 | 11 (65) | 19 (68) | 12 (86) | 3 (60) | 4 (44) | ||
| 4 | 3 (20) | 0 | 0 | 0 | 0 | ||
| Unknown | 0 | 4 (14) | 0 | 1 (20) | 3 (33) | ||
| N | |||||||
| 0 | 5 (29) | 9 (32) | 0.67 | 5 (36) | 2 (40) | 2 (22) | 0.53 |
| 1 | 5 (29) | 9 (32) | 3 (21) | 2 (40) | 4 (44) | ||
| 2 | 6 (35) | 9 (32) | 6 (43) | 1 (20) | 2 (22) | ||
| 3 | 1 (6) | 0 | 0 | 0 | 0 | ||
| Unknown | 0 | 1 (4) | 0 | 0 | 1(11) | ||
| M | |||||||
| 0 | 17 (100) | 26 (93) | 0.52 | 14 (100) | 5 (100) | 7 (78) | na |
| Unknown | 0 | 2 (7) | 0 | 0 | 2 (22) | ||
| Neoadjuvant chemoradiotherapy | 14 (82) | 26 (93) | 0.35 | 5 (100) | 13 (93) | 8 (89) | 0.66 |
| Surgical approach | |||||||
| TH | 6 (35) | 10 (36) | 1.00 | 2 (40) | 5 (36) | 3 (33) | 1.00 |
| TT | 11 (65) | 18 (64) | 3 (60) | 9 (64) | 6 (67) | ||
| Open procedure | 16 (94) | 25 (59) | 1.00 | 12 (86) | 5 (100) | 8 (89) | 0.74 |
| Laparoscopic procedure | 1 (6) | 3 (11) | 2 (14) | 0 | 1 (11) | ||
| Hand sewn end-to-end | 7 (41) | 17 (61) | 0.23 | 8 (57) | 3 (60) | 6 (67) | 0.61 |
| Semimechanical side-to-end | 10 (59) | 11 (39) | 6 (43) | 2 (40) | 3 (33) | ||
| Operation duration (min) | 414 (186) | 383 (136) | 0.40 | 383 (171) | 382 (140) | 410 (156) | 0.79 |
| Blood loss (mL) | 1000 (800) | 675 (869) | 0.33 | 600 (765) | 725 (794) | 700 (960) | 0.33 |
| APACHE II score | 8 (5) | 8 (3) | 0.47 | 8 (2) | 7 (6) | 9 (4) | 0.82 |
| SOFA score | |||||||
| Day 0 | 7 (2) | 6 (4) | 0.36 | 4 (3) | 5 (3) | 5(2) | 1.00 |
| Day 1 | 5 (3) | 4 (5) | 0.18 | 5 (2) | 4 (6) | 4 (2) | 0.47 |
| Day 2 | 3 (1) | 3 (4) | 0.92 | 3 (4) | 2 (5) | 4 (2) | 0.97 |
| Day 3 | 1 (2) | 1 (4) | 0.15 | 3 (2) | 2 (3) | 3 (5) | 0.26 |
| SIRS (days 0–10) | 13 (77) | 27 (96) | 0.06 | 5 (100) | 14 (100) | 8 (89) | 0.17 |
| Sepsis (days 0–10) | 0 | 17 (64) | < 0.001 | 0 | 11 (79) | 6 (67) | < 0.001 |
| Septic shock (days 0–10) | 0 | 6 (21) | 0.07 | 0 | 3 (21) | 3 (33) | 0.06 |
| Prophylactic antibiotics i.o. | 17 (100) | 22 (100) | na | 5 (100) | 14 (100) | 9 (100) | na |
| Antibiotics received (days 0–10) | 4 (24) | 20 (71) | 0.002 | 10 (71) | 3 (66) | 7 (78) | 0.02 |
| Microbiology | |||||||
|
| 0 | 7 (25) | 0.03 | 0 | 5 (36) | 2 (22) | 0.03 |
|
| 0 | 5 (18) | 0.14 | 0 | 3 (21) | 2 (22) | 0.15 |
|
| 0 | 1 (4) | 1.00 | 0 | 1 (7) | 0 | 0.50 |
|
| 0 | 1 (4) | 1.00 | 0 | 0 | 1 (11) | 0.25 |
| Miscellaneous | 0 | 6 (21) | 0.07 | 0 | 3 (21) | 3 (33) | 0.06 |
| Vasopressor need (days 0–10) | 7 (40) | 12 (43) | 0.91 | 2 (40) | 5 (36) | 5 (56) | 0.82 |
| ICU days | 3 (1) | 3 (1) | 0.64 | 3 (2) | 4 (2) | 3 (5) | 0.43 |
| In hospital days | 12 (6) | 16 (10) | 0.007 | 20 (12) | 15 (6) | 19 (12) | 0.02 |
| 30-day mortality | 0 | 0 | na | 0 | 0 | 0 | na |
Median (inter-quartile range), number (percentage), where appropriate; P1 comparison of uncomplicated vs. complicated patients by Mann-Whitney U or Fisher’s exact test where appropriate. P2 comparison of uncomplicated patient and all three complication groups by Kruskal-Wallis H or X 2 test, where appropriate
APACHE Acute Physiology and Chronic Health Evaluation, ASA class American Society of Anesthesiology physical status classification, BMI body mass index, FEV1 forced expiratory volume in 1 s, VC vital capacity, ICU intensive care unit, i.o. intra-operatively, m male, na not applicable, P-POSSUM Portsmouth Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity, SIRS Systemic Inflammatory Response Syndrome, SOFA Sequential Organ Failure Assessment, TH transhiatal, TT transthoracic, WHO World Health Organization
Fig. 1Early leukocyte and plasma biomarker levels (median and inter-quartile range) for complications up to 10 days after elective esophagectomy. Without complications (N = 17) (circle), with complications (N = 28) (square). CRP C-reactive protein, PCT procalcitonin. P values refer to Mann-Whitney U test
Diagnostic values of biomarkers (days 0–3) for complications (up to day 10)
| Cutoff | AUROC |
| SN | SP | PPV | NPV | |
|---|---|---|---|---|---|---|---|
| Diagnostic values for any complication | |||||||
| Leukocytes day 3 | 7.9 × 109/L | 0.71 | 0.02 | 75 | 64 | 78 | 60 |
| CRP day 2 | 100 mg/L | 0.71 | 0.04 | 100 | 36 | 74 | 100 |
| CRP day 3 | 68 mg/L | 0.75 | 0.006 | 100 | 43 | 75 | 100 |
| ∆ CRP days 0–3 | 23 | 0.75 | 0.01 | 75 | 78 | 86 | 64 |
| Diagnostic values for combined surgical/infectious complications | |||||||
| CRP day 3 | 316 mg/L | 0.80 | < 0.001 | 0 | 100 | - | 84 |
| ∆ CRP days 0–3 | 81 | 0.77 | 0.008 | 40 | 90 | 50 | 86 |
| PCT day 3 | 1.15 ng/mL | 0.86 | < 0.001 | 38 | 100 | 100 | 81 |
| Diagnostic values for anastomotic leak | |||||||
| CRP day 3 | 229 mg/L | 0.78 | 0.002 | 71 | 84 | 50 | 93 |
| ∆ CRP days 0–3 | 55 | 0.82 | < 0.001 | 80 | 80 | 50 | 94 |
| PCT day 1 | 1.82 ng/mL | 0.76 | 0.005 | 22 | 100 | 100 | 83 |
| PCT day 3 | 0.35 ng/mL | 0.86 | < 0.001 | 67 | 80 | 55 | 87 |
AUROC area under the receiver operating characteristics curve, CRP C-reactive protein, NPV negative predictive value, PCT procalcitonin, PPV positive predictive value, SN sensitivity, SP specificity, ∆ fractional change (day 3 divided by day 0 value)
Fig. 2Early leukocyte and plasma biomarker levels (median and inter-quartile range) for complications up to 10 days after elective esophagectomy. Without complications (N = 17) (circle), surgical complications (N = 5) (square), infectious complications (N = 14) (triangle), combined surgical/infectious complications (N = 9) (inverted triangle). CRP C-reactive protein, PCT procalcitonin. P values refer to Kruskal-Wallis test
Fig. 3Early leukocyte and plasma biomarker levels (median and inter-quartile range) for complications up to 10 days after elective esophagectomy. Without complications (N = 17) (circle), with other complications (N = 18) (square), with anastomotic leakage (N = 10) (triangle), CRP C-reactive protein, PCT procalcitonin. P values refer to Kruskal-Wallis test